Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 7/20 | 0.54 |
| ▸ | MKNK2 | Q9HBH9 | 6/20 | 0.54 |
| ▸ | BCR | P11274 | 5/20 | 0.54 |
| ▸ | MKNK1 | Q9BUB5 | 5/20 | 0.54 |
| ▸ | MAPK14 | Q16539 | 4/20 | 0.52 |
| ▸ | MAP3K20 | Q9NYL2 | 3/20 | 0.52 |
| ▸ | BRAF | P15056 | 8/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.48 |
| ▸ | TEK | Q02763 | 2/20 | 0.48 |
| ▸ | NTRK2 | Q16620 | 2/20 | 0.48 |
| ▸ | RET | P07949 | 2/20 | 0.48 |
| ▸ | MAP3K7 | O43318 | 3/20 | 0.48 |
| ▸ | MAP4K2 | Q12851 | 3/20 | 0.48 |
| ▸ | SRC | P12931 | 2/20 | 0.47 |
| ▸ | HCK | P08631 | 2/20 | 0.46 |
| ▸ | NR2C2 | P49116 | 1/20 | 0.46 |
| ▸ | LCK | P06239 | 2/20 | 0.46 |
| ▸ | STK25 | O00506 | 1/20 | 0.46 |
| ▸ | CIT | O14578 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26007842 | 0.92 | BRAF (0.50) | ABL1MKNK2BCRMKNK1MAPK14 | |
| SCHEMBL24007134 | 0.89 | ABL1 (0.60) | ABL1MKNK2BCRMKNK1BRAF | |
| SCHEMBL23205750 | 0.88 | ABL1 (0.53) | ABL1MKNK2BCRMKNK1MAPK14 | |
| SCHEMBL24374953 | 0.88 | BRAF (0.52) | ABL1MKNK2BCRMKNK1BRAF | |
| SCHEMBL24374421 | 0.87 | BRAF (0.68) | ABL1MKNK2BCRMKNK1BRAF | |
| SCHEMBL24007133 | 0.87 | ABL1 (0.55) | ABL1MKNK2BCRMKNK1MAPK14 | |
| SCHEMBL23205579 | 0.87 | ABL1 (0.52) | ABL1MKNK2BCRMKNK1MAPK14 | |
| SCHEMBL24815081 | 0.86 | BRAF (0.49) | ABL1MKNK2BCRMKNK1BRAF | |
| SCHEMBL24007814 | 0.86 | MKNK2 (0.53) | ABL1MKNK2BCRMKNK1MAPK14 | |
| SCHEMBL24007046 | 0.85 | ABL1 (0.56) | ABL1MKNK2BCRMKNK1MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230265075-A1 | 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS | AJAX THERAPEUTICS, INC. | 2023-08-24 | — | — | US | disclosed |
| US-11691963-B2 | 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors | AJAX THERAPEUTICS, INC. (US) | 2023-07-04 | — | — | US | disclosed |
| US-20230183204-A9 | BENZIMIDAZOLE DERIVATIVES AND AZA-BENZIMIDAZOLE DERIVATIVES AS JANUS KINASE 2 INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-06-15 | — | — | US | disclosed |
| US-20230183204-A9 | BENZIMIDAZOLE DERIVATIVES AND AZA-BENZIMIDAZOLE DERIVATIVES AS JANUS KINASE 2 INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-06-15 | — | — | US | disclosed |
| US-20220411403-A1 | 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS | AJAX THERAPEUTICS, INC. | 2022-12-29 | — | — | US | disclosed |
| US-20220127246-A1 | BENZIMIDAZOLE DERIVATIVES AND AZA-BENZIMIDAZOLE DERIVATIVES AS JANUS KINASE 2 INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-04-28 | — | — | US | disclosed |
| WO-2021226261-A1 | 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS | AJAX THERAPEUTICS, INC. (US) | 2021-11-11 | — | — | WO | disclosed |
| EP-3876930-A1 | BENZIMIDAZOLE DERIVATIVES AND AZA-BENZIMIDAZOLE DERIVATIVES AS JANUS KINASE 2 INHIBITORS AND USES THEREOF | Dana-Farber Cancer Institute, Inc. (US) | 2021-09-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220127246-A1 | BENZIMIDAZOLE DERIVATIVES AND AZA-BENZIMIDAZOLE DERIVATIVES AS JANUS KINASE 2 INHIBITORS AND USES THEREOF | JAK1, JAK2, JAK3 | ABL1 18/4885MKNK2 585/4885BCR 1084/4885 |
| US-20220411403-A1 | 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS | JAK2, JAK3, STAT5B | ABL1 7/4885MKNK2 700/4885BCR 74/4885 |
| US-20230183204-A9 | BENZIMIDAZOLE DERIVATIVES AND AZA-BENZIMIDAZOLE DERIVATIVES AS JANUS KINASE 2 INHIBITORS AND USES THEREOF | JAK1, JAK2, JAK3 | ABL1 18/4885MKNK2 585/4885BCR 1084/4885 |
| US-20230265075-A1 | 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS | JAK2, JAK3, STAT5B | ABL1 7/4885MKNK2 700/4885BCR 74/4885 |
| US-11691963-B2 | 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors | JAK2, JAK3, STAT5B | ABL1 7/4885MKNK2 700/4885BCR 74/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.